Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b safety study of MenACWY vaccine with routine infant vaccines
2014-004537-95Phase 3
- Sponsor
- Novartis
- Start
- Oct 2014
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of meningococcal conjugate vaccine in meningococcal disease, sponsored by Novartis. Primary endpoint: Severe systemic reactions after any vaccination.
02
Drugs
meningococcal conjugate vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2014-004537-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004537-95.